Weight-Loss Drug Could Cure Sleep Apnea in Up to Half of Obese Patients

By Gina Shaw
The weight loss drug tirzepatide (Zepbound, Eli Lilly) dramatically reduces obstructive sleep apnea (OSA), with about half of all patients experiencing what amounts to a clinical cure, according to new data from the SURMOUNT-OSA Phase 3 clinical trials presented at the American Diabetes Association (ADA) Annual Meeting on June 21, 2024.